Building the Future of

Cardiovascular Care with AI

AI-powered platform that optimizes diagnosis and treatment planning for coronary artery disease (CAD).

ComKardia is building a decision-support platform for coronary interventions that helps physicians plan stent strategy—including selection, sizing, and placement—using patient-specific computational modeling. By generating a digital representation of each patient’s coronary anatomy and enabling scenario-based evaluation of treatment approaches, we aim to complement clinical judgment with consistent, data-driven insights informed by expert practice patterns and evidence.

Developed with actual patient data at leading academic medical centers and ongoing discussions with Boston Scientific, Abbott, and Philips, ComKardia has established itself as a critical enabler of next-generation interventional cardiology.

Strong Clinical Validation: Multi-center trials demonstrating reduction in stent restenosis, improved patient outcomes, and reduced procedural times.

Scalable SaaS Business Model: AI-driven platform generating recurring revenue from each PCI procedure.

Scalable SaaS Business Model: AI-driven platform generating recurring revenue from each PCI procedure.

Scalable SaaS Business Model: AI-driven platform generating recurring revenue from each PCI procedure.

Strategic Partnerships: Collaborations with PCI systems / device manufacturers and healthcare systems to accelerate commercialization.

Strategic Partnerships: Collaborations with PCI systems / device manufacturers and healthcare systems to accelerate commercialization.

Strategic Partnerships: Collaborations with PCI systems / device manufacturers and healthcare systems to accelerate commercialization.

Regulatory & Reimbursement Pathways: 510(k) FDA submission planned in 2026, with reimbursement alignment through CPT code expansion for AI-assisted IVUS/OCT as well as CMS quality bonus attainment.

Regulatory & Reimbursement Pathways: 510(k) FDA submission planned in 2026, with reimbursement alignment through CPT code expansion for AI-assisted IVUS/OCT as well as CMS quality bonus attainment.

Regulatory & Reimbursement Pathways: 510(k) FDA submission planned in 2026, with reimbursement alignment through CPT code expansion for AI-assisted IVUS/OCT as well as CMS quality bonus attainment.

Close Collaboration with KardiaFora Foundation: Bring visibility and accelerated commercial adoption as a service provider and engine behind this non-for-profit research collaborative fostering adoption, trust, and delivering clinical impact through values-driven partnerships and data stewardship.

"ComKardia isn’t just improving outcomes, it’s redefining how the world treats heart disease."

Maria Kyparissopoulou

Co-Founder, President & CEO

"ComKardia isn’t just improving outcomes, it’s redefining how the world treats heart disease."

Maria Kyparissopoulou

Co-Founder, President & CEO

"ComKardia isn’t just improving outcomes, it’s redefining how the world treats heart disease."

Maria Kyparissopoulou

Co-Founder, President & CEO

Scalable AI Decision Support for Interventional Cardiology

ComKardia is building an AI-powered decision-support platform for stent-based procedures. Using a patient-specific digital twin and scenario-based analysis, we help clinicians plan stent strategy with greater precision and consistency—bringing data-driven insights into the cath lab workflow.

Solution Overview

Our Mission

”Improve the future of cardiovascular medicine through intelligent, personalized computation delivering faster decision support and better outcomes."

ComKardia’s Competitive Edge

ComKardia is redefining PCI optimization through predictive and therapy-guiding intelligence. We combine physics-based digital twins, AI-driven simulation, and clinical validation to deliver a first-in-class decision support platform that transforms how interventional cardiologists plan and execute procedures.

Clinical Validation & Impact

A woman with red hair and a black sleeveless top smiling confidently in a bright, modern indoor setting.